Perampanel is a non-competitive AMPA glutamate receptor antagonist used to treat partial-onset seizures with or without secondarily generalized seizures, and as adjunctive treatment of primary generalized tonic-clonic seizures in patients with epilepsy. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
- Mechanism
- Curator reviewed
The exact mechanism of action of perampanel in seizures is not yet determined, but it is known that perampanel decreases neuronal excitation by non-competitive ihibition of the AMPA receptor.
- Primary indication
- Perampanel is indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in epileptic patients four years of age and older.Curator reviewed · 3 structured indications
- Formula / weight
- C23H15N3O · 349.393 g/mol (avg)
- First approval
- Canada, 2013 · United States, 2012 · European Union, 2016
- Code names
- E-2007 · ER-155055-90
- Brand names
Resolves to
PRMWGUBFXWROHD-UHFFFAOYSA-NSMILESO=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Perampanel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account